News on Medial

Eat Better Co bags Rs 17 Cr in pre-Series A round

EntrackrEntrackr · 10m ago
Eat Better Co bags Rs 17 Cr in pre-Series A round
Medial

Snack brand Eat Better Co has picked up Rs 17 crore in pre-Series A funding round co-led by Prath Ventures and Spring Marketing Capital along with participation from existing investors. The brand also made an appearance on Shark Tank where they bagged a deal at a 100-crore valuation from Namita Thapar. The Jaipur based company had previously raised $1.12 million from Mumbai Angels and others. The fresh funds will be utilized to expand its product line and double down on Q-commerce, Eat Better Co said in a press release. Co-founded in 2020 by Mridula Kanoria, Vidushi Kajaria, and Shaurya Kanoria, Eat Better Co operates as an Internet first brand offering multi-category healthy products. The brand makes better-for-you sweets and namkeen using real ingredients, just like homemade snacks. The company offers healthy food products like healthy snacks, sweets, seeds, and nuts mixes, giving an alternative for healthy snacking. The brand claims to deliver over 2,00,000 orders every month and is selling across multiple platforms. The brand’s products are also available on quick commerce platforms like Swiggy Instamart, Zepto, and Blinkit.

Related News

Cumin Co. raises $5 Mn pre-Series A round led by Fireside Ventures

EntrackrEntrackr · 17d ago
Cumin Co. raises $5 Mn pre-Series A round led by Fireside Ventures
Medial

Cumin Co. raises $5 Mn pre-Series A round led by Fireside Ventures Gurugram-based kitchenware startup Cumin Co. has raised $5 million (around Rs 41 crore) in a pre-Series A funding round led by Fireside Ventures. Existing investors Huddle Ventures and Alteria Capital also participated, along with several angel investors. Earlier in August last year, Cumin Co. had raised its first institutional funding of $1.5 million (about Rs 13.16 crore) led by Fireside Ventures along with participation from Huddle Ventures. The proceeds will be used to expand the product portfolio across cookware and kitchen essentials. It also plans to strengthen its supply chain, increase investments in R&D, and improve manufacturing and product innovation capabilities. Founded by Niharika Joshi and Udit Lekhi, Cumin Co. operates in the premium kitchenware segment and focuses on research-led product development. The brand sells cookware and kitchen essentials directly to consumers through online channels. Cumin Co. builds its products around proprietary material and coating technology under its Enviromax platform. It holds three granted patents and has five more pending, covering material science, surface coatings, and product design. Going ahead, Cumin Co. will continue to focus on controlled expansion, selective channel rollout, and improving unit economics as it scales its operations. It competes with other notable startups in this space such as Indus Valley and Palette Brand’s Ember. Indus Valley secured Rs 23.1 crore in a pre-Series A round led by DSG Ventures, while Palette Brands raised nearly Rs 17 crore in a pre-Series A round led by Rockstud Capital.

Exclusive: Finnable to raise Rs 250 Cr in new round

EntrackrEntrackr · 4m ago
Exclusive: Finnable to raise Rs 250 Cr in new round
Medial

Exclusive: Finnable to raise Rs 250 Cr in new round Digital lending platform Finnable is set to raise Rs 250 crore (approximately $29 million) in its pre-series C round from Matrix Partners, TVS Capital, and India Nippon Electricals Limited. The company has passed a board resolution and allotted 3,35,238 Pre-Series C preference shares at an issue price of Rs 3,788.35 each and secured Rs 127 crore or $14.7 million. During the first tranche of the pre-series C round of Rs 127 crore, Matrix Partners has injected Rs 125 crore, while India Nippon pumped in Rs 2 crore. The remaining funds are expected to be infused shortly, completing the round. The development comes six months after Ranjan Pai’s family office invested Rs 40 crore in the company. According to Entrackr’s estimates, the company would be valued at Rs 1,300 crore or $150 million post-money. Before this round, MEMG Family Office LLP held 18.69% in Finnable, while Matrix Partners India and TVS Shriram Growth owned 14.53% and 8.05%, respectively. Co-founder and CEO Nitin Gupta retained over 24%. The cap table is set to shift with the fresh infusion from Matrix and TVS, alongside dilution of the founders’ stake. Founded in 2016 by ex-bankers Nitin Gupta, Amit Arora, and Viraj Tyagi, Finnable is a Bengaluru-based fintech startup offering personal loans to salaried professionals. The company is at the AUM of Rs 3,000 crore and has served over 2.7 lakhs customers. Finnable has yet to file its FY25 numbers. In FY24, the company posted a revenue of Rs 181.7 crore with losses of Rs 5.88 crore.

Exclusive: BankBazaar bags Rs 130 Cr in equity and debt funding

EntrackrEntrackr · 1y ago
Exclusive: BankBazaar bags Rs 130 Cr in equity and debt funding
Medial

BankBazaar, an online marketplace for financial products, has raised Rs 80 crore ($9.6 million) in its ongoing Series D round via private placement. This is the first round of investment for the firm in 2024. The board at BankBazaar has passed a special resolution to issue up to 22,821 Series D2 CCPS at an issue price of Rs 3,727 each to raise Rs 80 crore, its regulatory filing sourced from the RoC shows. According to the filings, the company will deploy this fund for purposes like meeting capital requirements, expansion, and growth. BankBazaar has already received Rs 46.35 crore in three tranches while the rest of the amount will flow to its account soon. The Peak XV Partners-backed firm also raised Rs 50 crore via non-convertible debentures and convertible share warrants from Vistra ITCL (India) Limited, separate filing reveals. As per TheKredible estimates, the Chennai-based company has been valued at around $217 million (post-allotment). BankBazaar is a co-branded credit card issuer that lets you check your credit score as well as cross-sells third-party loans and insurance products. As per the company website, it has partnered with more than 50 banks and has a customer base of over 50 million. The 15-year-old company has amassed over $110 million in funding to date from Amazon, GUS Holdings, Walden Investments, Eight Roads, and others. See TheKredible for the complete shareholding pattern. While the company claimed to achieve breakeven with revenue of Rs 250 crore in FY24, its revenue from operations saw a surge of 65.6% to Rs 159 crore in FY23 from Rs 96 crore in FY22. However, its losses stood at Rs 27 crore in FY23.

Exclusive: Kiran Mazumdar Shaw’s Immuneel Therapeutics raises Rs 100 Cr

EntrackrEntrackr · 1y ago
Exclusive: Kiran Mazumdar Shaw’s Immuneel Therapeutics raises Rs 100 Cr
Medial

Cancer focused biotech startup Immuneel Therapeutics has raised Rs 100 crore or $12 million in the extension of Series A round from Taiba Middle East FZ LLC. This is the third round of investment for the Bengaluru-based company since its inception in 2018. The board at Immuneel Therapeutic has passed a special resolution to issue 1o equity shares and 8,164 Series A1 CCPS at an issue price of Rs 1,22,330 each to raise Rs 100 crore or $12 million, its regulatory filing accessed from the Registrar of Companies show. The company will use these investments for growth and expansion as decided by the board, the filings further added. As per TheKredible’s estimates, the firm has been valued at around Rs 587 crore or $71 million (post-allotment). Following the fresh proceeds, Taiba Middle East FZ holds a 17% stake in Immuneel Therapeutics. The round appears to be ongoing and it may raise more funds. The company has raised around $40 million to date including its $15 million Series A financing co-led by Eight Roads Ventures, True North, and F-Prime Capital in 2022. Founded by Biocon founder Kiran Mazumdar Shaw, oncologist and Pulitzer winner — Siddhartha Mukherjee and Kush Parwar, Immuneel Therapeutics is an Indian clinical-stage startup which is engaged in developing cell and gene therapies for cancer patients. It’s also working on developing its own pipeline of chimeric antigen receptor T-cell (CAR-T) therapies and other cellular immunotherapies for management and treatment of cancer. The firm claims to offer therapies at one-third of the costs borne for gene therapies in America. While the company is yet to file its annual statements for FY24, six-year-old Immuneel Therapeutics remained at a pre-revenue stage in FY23. Its losses stood at Rs 39 crore in the fiscal year ending March 2023.

Download the medial app to read full posts, comements and news.